Ibrutinib may be a potential drug to treat B‐ALL because it can inhibit the phosphorylation of CXCR4 induced by SDF‐1 and the expression and activation of ERK and BCL‐xL.115. Here, CXCL12 is linked to acute lymphoblastic leukemia.